MOURAD TAYEBI

Prof. Dr. MOURAD TAYEBI

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2003 in Nature
Verified
Journal Article
Closed access
PDF file
Anthony R. WhiteAnthony R. White
Anthony R. White
PEPerry Enever
Perry Enever
MOURAD TAYEBIMOURAD TAYEBI
MOURAD TAYEBI
RMRosey Mushens
Rosey Mushens
JLJackie Linehan
Jackie Linehan
SHSimon Hawke
Simon Hawke

8 October 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
UAUtpal Kumar Adhikari
Utpal Kumar Adhikari
MOURAD TAYEBIMOURAD TAYEBI
MOURAD TAYEBI
MRM Mizanur Rahman
M Mizanur Rahman
Oropouche virus (OROV) is an emerging pathogen which causes Oropouche fever and meningitis in humans. Several outbreaks of OROV in South America, especially in Brazil, have changed its status as an emerging disease, but no vaccine or specific drug target is available yet. Our approach was to identify the epitope-based vaccine candidates as well as the ligand-binding pockets through the use of immunoinformatics. In this report, we identified both T-cell and B-cell epitopes of the most antigenic OROV polyprotein with the potential to induce both humoral and cell-mediated immunity. Eighteen highly antigenic and immunogenic CD8+ T-cell epitopes were identified, including three 100% conserved epitopes (TSSWGCEEY, CSMCGLIHY, and LAIDTGCLY) as the potential vaccine candidates. The selected epitopes showed 95.77% coverage for the mixed Brazilian population. The docking simulation ensured the binding interaction with high affinity. A total of five highly conserved and nontoxic linear B-cell epitopes “NQKIDLSQL,” “HPLSTSQIGDRC,” “SHCNLEFTAITADKIMSL,” “PEKIPAKEGWLTFSKEHTSSW,” and “HHYKPTKNLPHVVPRYH” were selected as potential vaccine candidates. The predicted eight conformational B-cell epitopes represent the accessibility for the entered virus. In the posttherapeutic strategy, ten ligand-binding pockets were identified for effective inhibitor design against emerging OROV infection. Collectively, this research provides novel candidates for epitope-based peptide vaccine design against OROV.

1 September 2003 in Brain
Verified
Journal Article
Open access
PDF file
VBVincent Beringue
Vincent Beringue
GMGary Mallinson
Gary Mallinson
MKMaria Kaisar
Maria Kaisar
MOURAD TAYEBIMOURAD TAYEBI
MOURAD TAYEBI
ZSZahid Sattar
Zahid Sattar
SHSimon Hawke
Simon Hawke
Prion diseases are a group of invariably fatal neurodegenerative disorders that include Creutzfeldt–Jakob disease in humans, scrapie in sheep and goats, and bovine spongiform encephalopathy in cattle. The infectious agent or prion is largely composed of an abnormal isoform (PrPSc) of a host encoded normal cellular protein (PrPc). The conversion of PrPc to PrPSc is a dynamic process and, for reasons that are not clear, the distribution of spongiform change and PrPSc deposition varies among prion strains. An obvious explanation for this would be that the transformation efficiency in any given brain region depends on favourable interactions between conformations of PrPc and the prion strain being propagated within it. However, identification of specific PrPc conformations has until now been hampered by a lack of suitable panels of antibodies that discriminate PrPc subspecies under native conditions. In this study, we show that monoclonal antibodies raised against recombinant human prion protein folded into α or β conformations exhibit striking heterogeneity in their specificity for truncations and glycoforms of mouse brain PrPc. We then show that some of these PrPc isoforms are expressed differentially in certain mouse brain regions. This suggests that variation in the expression of PrPc conformations in different brain regions may dictate the pattern of PrPSc deposition and vacuolation, characteristic for different prion strains.

1 January 2008 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
CBClive Bate
Clive Bate
MOURAD TAYEBIMOURAD TAYEBI
MOURAD TAYEBI
AWAlun Williams
Alun Williams
The early stages of Alzheimer's disease (AD) are closely associated with the production of the Aβ1–42 peptide, loss of synapses and gradual cognitive decline. Since some epidemiological studies showed that EGb 761, an extract from the leaves of the Ginkgo biloba tree, had a beneficial effect on mild forms of AD, the effects of some of the major components of the EGb 761 extract (ginkgolides A and B, myricetin and quercetin) on synapse damage in response to Aβ1–42 were examined.

1 September 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VBVincent Beringue
Vincent Beringue
DVDidier Vilette
Didier Vilette
GMGary Mallinson
Gary Mallinson
FAFabienne Archer
Fabienne Archer
MKMaria Kaisar
Maria Kaisar
SHSimon Hawke
Simon Hawke
Conversion of the cellular α-helical prion protein (PrPC) into a disease-associated isoform (PrPSc) is central to the pathogenesis of prion diseases. Molecules targeting either normal or disease-associated isoforms may be of therapeutic interest, and the antibodies binding PrPC have been shown to inhibit prion accumulation in vitro. Here we investigate whether antibodies that additionally target disease-associated isoforms such as PrPSc inhibit prion replication in ovine PrP-inducible scrapie-infected Rov cells. We conclude from these experiments that antibodies exclusively binding PrPC were relatively inefficient inhibitors of ScRov cell PrPSc accumulation compared with antibodies that additionally targeted disease-associated PrP isoforms. Although the mechanism by which these monoclonal antibodies inhibit prion replication is unclear, some of the data suggest that antibodies might actively increase PrPSc turnover. Thus antibodies that bind to both normal and disease-associated isoforms represent very promising anti-prion agents.

15 March 2005 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AKAzadeh Khalili-Shirazi
Azadeh Khalili-Shirazi
SQSonia Quaratino
Sonia Quaratino
MLMarco Londei
Marco Londei
LSLinda Summers
Linda Summers
MOURAD TAYEBIMOURAD TAYEBI
MOURAD TAYEBI
JCJohn Collinge
John Collinge
In prion diseases, such as variant Creutzfeldt-Jakob disease normal cellular prion protein (PrPC), a largely α-helical structure is converted to an abnormal conformational isoform (PrPSc) that shows an increase in β-sheet content. Similarly, the recombinant form of PrPC (rα-PrP) can be converted to a conformation dominated by β-sheet (rβ-PrP) by reduction and mild acidification in vitro, a process that may mimic in vivo conversion following PrPC internalization during recycling. Despite PrPSc accumulation and prion propagation in the lymphoreticular system before detectable neuroinvasion, no Ab response to PrP has been detected, probably due to immune tolerance. To investigate how the immune system may respond to α- and β-PrP, we immunized Prnp0/0 mice that are not tolerant of PrP with rα-PrP and rβ-PrP. In this study, we show that although T cells stimulated by these differently folded conformers PrP recognize similar immunodominant epitopes (residues 111–130 and 191–210) the cytokine profile in response to rα- and rβ-PrP was different. Challenge with rα-PrP elicited a strong response of IL-5 and IL-10, whereas rβ-PrP led to an early increased production of IFN-γ. In addition, immunization with rα-PrP led to production of predominantly IgG1 isotype Ab in the sera, whereas after immunization with rβ-PrP, IgG2b was significantly produced. Thus, both humoral and cellular responses to these differently folded isoforms of the same protein are different, indicating a possible involvement of Th1 and Th2 pathway activation. These differences may be exploitable diagnostically and therapeutically for prion diseases, such as variant Creutzfeldt-Jakob disease.